CORDIS · 115308 · FP7
BIOVACSAFE Biomarkers For Enhanced Vaccine Safety
Coordinator: GLAXOSMITHKLINE VACCINES SRL (IT)
BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveillance. A compact interlocking structure provides efficient and cost-effective goal delivery, while offering the full spectrum of functionality and capacity to match the needs for predictive biomarker…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €17.4M toward a total project budget of €30.9M — a funding rate of 56%, with the remainder covered by the consortium partners. The project runs over approximately 6.5 years from 2012-03-01 to 2018-08-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from IT
see all →- THCS — European Partnership on Transforming Health and Care Systems101095654 · HORIZON · €91.6M
- c4c — conect4children (COllaborative Network for European Clinical Trials For Children)777389 · H2020 · €67.0M
- ADITEC — Advanced Immunization Technologies280873 · FP7 · €30.0M
- ARCHETYPE SW550 — Demonstration of innovating parabolic solar trough using an alternative heat transfer fluid producing electricity and fresh water: ARChimede Hot Energy TYPology Enhanced Water Solar 550268181 · FP7 · €29.7M
- EPOS IP — EPOS Implementation Phase676564 · H2020 · €18.4M
- COMETHA — 80,000 TON/Y PRECOMMERCIAL INDUSTRIAL SCALE DEMONSTRATION PLANT ON SECOND GENERATION LIGNOCELLULOSIC ETHANOL322406 · FP7 · €17.9M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the JTI-CP-IMI funding scheme.
- What is the EU contribution?
- The European Commission contributes €17.4M toward a total project budget of €30.9M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by GLAXOSMITHKLINE VACCINES SRL (IT).
- What is the project timeline?
- The project runs from 2012-03-01 to 2018-08-31 — approximately 6.5 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 115308.